SCHEMBL6356140

SCHEMBL6356140

Cc1cc(C(=O)Cl)cc(OCc2ccccc2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA1 P23415 1/20 0.56
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
FFAR4 Q5NUL3 1/20 0.49
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
MCL1 Q07820 1/20 0.47
MRGPRX4 Q96LA9 5/20 0.47
SMPD1 P17405 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12563268 0.88 RXRA (0.60) RXRARXRBRXRGFFAR4MAPT
SCHEMBL2670990 0.87 MRGPRX4 (0.55) GLRA1RXRARXRBRXRGMAPT
SCHEMBL16902987 0.87 GLRA1 (0.61) GLRA1RXRARXRBRXRGFFAR4
SCHEMBL2671557 0.86 GLRA1 (0.53) GLRA1RXRARXRBRXRGMAPT
SCHEMBL71526 0.84 RXRA (0.58) GLRA1RXRARXRBRXRGFFAR4
SCHEMBL7783922 0.84 FFAR4 (0.60) GLRA1RXRARXRBRXRGFFAR4
SCHEMBL348412 0.84 GLRA1 (0.68) GLRA1RXRARXRBRXRGFFAR4
SCHEMBL514495 0.82 GLRA1 (0.65) GLRA1RXRARXRBSMN1; SMN2RAB9A
SCHEMBL11345190 0.81 GLRA1 (0.60) GLRA1RXRASMN1; SMN2RAB9ANPC1
SCHEMBL5838451 0.80 MEN1 (0.63) RXRARXRBRXRGMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000443-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2018-06-19 US disclosed
US-9399631-B2 Polyphenol proteasome inhibitors, synthesis, and methods of use UNIVERSITY OF SOUTH FLORIDA (US) 2016-07-26 US disclosed
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2016-05-19 US disclosed
US-9181162-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2015-11-10 US disclosed
US-20140045931-A1 POLYPHENOL PROTEASOME INHIBITORS, SYNTHESIS, AND METHODS OF USE THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2014-02-13 US disclosed
US-8563607-B2 Polyphenol proteasome inhibitors, synthesis, and methods of use UNIVERSITY OF SOUTH FLORIDA (US) 2013-10-22 US disclosed
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2012-05-17 US disclosed
US-20120029067-A1 Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use UNIVERSITY OF SOUTH FLORIDA (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045931-A1 POLYPHENOL PROTEASOME INHIBITORS, SYNTHESIS, AND METHODS OF USE PSMC1, PSMB5, PSMC5 GLRA1 4348/4885RXRA 3407/4885RXRB 3465/4885
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 GLRA1 1309/4885RXRA 2450/4885RXRB 1689/4885
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 GLRA1 1309/4885RXRA 2450/4885RXRB 1689/4885
US-20120029067-A1 Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use PSMC1, PSMB5, PSMC5 GLRA1 4348/4885RXRA 3407/4885RXRB 3465/4885
US-10000443-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 GLRA1 1309/4885RXRA 2450/4885RXRB 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.